Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27386679 | 0.85 | HSD17B3 (0.53) | HDAC1HDAC6KDM4EMAPTKMT2A | |
| SCHEMBL15136337 | 0.82 | HDAC1 (0.55) | HDAC1HDAC6KDM4EMAPTKMT2A | |
| SCHEMBL641907 | 0.82 | GSK3B (0.57) | HDAC1HDAC6KDM4EMAPTKMT2A | |
| SCHEMBL15920457 | 0.82 | HDAC1 (0.55) | HDAC1HDAC6KDM4EMAPTKMT2A | |
| SCHEMBL13706438 | 0.82 | HDAC1 (0.55) | HDAC1HDAC6KDM4EMAPTKMT2A | |
| SCHEMBL14683904 | 0.82 | HDAC1 (0.55) | HDAC1HDAC6KDM4EMAPTKMT2A | |
| Hydrochloric Acid SCHEMBL3231047 | 0.81 | HDAC1 (0.53) | HDAC1HDAC6KDM4EMAPTKMT2A | |
| SCHEMBL10812902 | 0.81 | HDAC1 (0.58) | HDAC1HDAC6KDM4EMAPTKMT2A | |
| Hydrochloric Acid SCHEMBL9672401 | 0.81 | HDAC1 (0.53) | HDAC1HDAC6KDM4EMAPTKMT2A | |
| SCHEMBL15088738 | 0.80 | MAPT (0.46) | KDM4EMAPTKMT2AL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102731374-A | Improved process for preparing 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone, an intermediate of etoricoxib | ITALIANA SINT SPA | 2012-10-17 | — | — | CN | claimed |
| WO-2024057277-A1 | DIAGNOSTIC PET IMAGING OF CARDIAC AMYLOIDOSIS | Beijing Lado Technology Co., Ltd. (CN) | 2024-03-21 | — | — | WO | disclosed |
| US-20230295108-A1 | ARYLTETRAHYDROPYRIDINE DERIVATIVE OR SALT THEREOF, INSECTICIDAL AGENT CONTAINING THE COMPOUND, AND METHOD OF USE THEREOF | NIHON NOHYAKU CO., LTD. (JP) | 2023-09-21 | — | — | US | disclosed |
| US-9580425-B2 | Pyrido[3,4-b] indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9469641-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| CN-105566324-A | Hydroxyl purine compound and application thereof | GOOD DOCTOR PHARMACEUTICAL GROUP CO LTD | 2016-05-11 | — | — | CN | disclosed |
| US-9260429-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9199996-B2 | Pyrido[4,3-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9193728-B2 | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| WO-2011038161-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| EP-2069302-B1 | SUBSTITUTED PYRIDYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER (US) | 2010-08-25 | — | — | EP | disclosed |
| US-7763617-B2 | Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-27 | — | — | US | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090318497-A1 | SUBSTITUTED PYRIDYLMETHYL BICYCLICCARBOXYAMIDE COMPOUNDS | PFIZER, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2009-10-29 | — | — | US | disclosed |
| EP-2069302-A1 | SUBSTITUTED PYRIDYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS | Pfizer Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1987831-A1 | COMPOUNDS EFFECTING GLUCOKINASE | AstraZeneca AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| US-20080207902-A1 | Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| WO-2008032204-A1 | SUBSTITUTED PYRIDYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295108-A1 | ARYLTETRAHYDROPYRIDINE DERIVATIVE OR SALT THEREOF, INSECTICIDAL AGENT CONTAINING THE COMPOUND, AND METHOD OF USE THEREOF | TRPA1, DDT, HPD | HDAC1 177/4885HDAC6 192/4885KDM4E 773/4885 |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | HDAC1 4373/4885HDAC6 3551/4885KDM4E 1637/4885 |
| US-20080207902-A1 | Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient | PDE5A, PDE3A, PDE3B | HDAC1 175/4885HDAC6 422/4885KDM4E 436/4885 |
| US-20090318497-A1 | SUBSTITUTED PYRIDYLMETHYL BICYCLICCARBOXYAMIDE COMPOUNDS | CNR1, CNR2, HCAR3 | HDAC1 2533/4885HDAC6 3730/4885KDM4E 3355/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | HDAC1 1593/4885HDAC6 260/4885KDM4E 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.